Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
If the government feels that the industry is not complying with the uniform code, it will consider making it a statutory code
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Company expects strong organic growth in sales, EBITDA in 2022
Guy Villax was also involved with the EFCG and Rx-360 associations and contributed to legislation being passed on both sides of the Atlantic to fight fake medicines and to level the playing field for GMP manufacturing.
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Subscribe To Our Newsletter & Stay Updated
